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Conditioned medium inhibits cancer cell proliferation 9fibroblast, and human mesenchymal stem cells (hMSCs). Surfacer marker expression of nor-
WJMSCs-and hypo-WJMSCs from P4 and P8 were >95% for CD90, CD73 and CD105 and <2%
for CD14, CD19, CD34, CD45, and HLDA-II. Nor-WJMSCs and hypo-WJMSCs from P4 and P8 un-
derwent differentiation to osteocyte, chondrocyte, and adipocyte. WJMSCs-norCM and
WJMSCs-hypoCM could inhibit proliferation of various cancer cell lines with minimum inhibitory
concentration (IC50) 51.690e81.440% and cause low inhibition of the normal cells with IC50
136.290e185.339%. WJMSCs-norCM and WJMSCs-hypoCM were not cytotoxic toward normal
cells. Nor-WJMSCs and hypo-WJMSCs from P4 and P8 showed no significant differences in
MSC surface marker expression or differentiation. WJMSCs-norCM and WJMSCs-hypoCM could
inhibit proliferation in various cancer cell lines, and were safe for normal cells.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Umbilical cord matrix contains an inexhaustible, noncon-
troversial source of stem cells.1e4. Postnatal stem cells are
offered for use less often because of possible moral/ethical
conflict.4 The umbilical cord mesenchymal stem cells
(UCMSCs) derived from human umbilical cord Wharton’s
jelly (WJMSCs) exhibit low immunogenicity and low immu-
nity after cytotherapy.5 The UCMSCs are more useful and
simpler in donor accessibility isolation, expansion, prolif-
erative capacity, and banking capability; can be used in
clinical and experimental therapy6,7; have a higher prolif-
eration rate and self-renewal capacity than adult tissue-
derived MSCs2,8; and a short doubling time.9,10 MSCs
possess strong immunosuppressive properties and can be
used for autologous and allogeneic therapy.11,12
Research has shown that MSCs, including UCMSCs, bone
marrow MSCs, and adipose tissue MSCs, have anticancer
activity and have been shown to inhibit the proliferation of
cancer cells in both in vitro and in vivo assays.5
Hypoxic conditions (1e3% O2) are more beneficial for
MSCs because low oxygen tension is more suitable for MSC
physiology in the bone marrow (2e7% O2). Previous
research has shown that MSCs cultured in hypoxic condi-
tions (2e5% O2) could maintain their viability.
13 The hypoxic
microenvironment can lead to a substantial increase in the
proliferation rate and population doubling time, but no
differences in surface markers of MSCs has been shown. The
hypoxic 2.5% O2 yield has the highest proliferation and the
lowest population doubling and population doubling time.10
The hypoxic condition induces molecular responses
including angiogenesis, metabolic change, and metastasis;
it also induces the secretion of growth factor and cytokine
in MSCs, and elevated the secretion of transforming growth
factor-b1 (TGF-b1). In addition, the hypoxic condition can
enhance cancer cell growth through the MSCs effect by
secretion and expression of TGF-b1.14
We conducted the continuing research to elucidate the
osteocyte, chondrocyte, and adipocyte differentiation of
normoxia-treated WJMSCs (nor-WJMSCs) and hypoxia-
treated WJMSCs (hypo-WJMSCs) from early and late pas-
sage (P4 and P8), to evaluate the WJMSCs-nor conditioned
medium (norCM) and WJMSCs-hypoCM toward cancer cell
lines including HeLa, HepG2, pc3, skov3, and hsc3 compared
to human fibroblast, NIH3T3, and human mesenchymal stem
cells (hMSCs).Materials and methods
Isolation and cultivation of WJMSCs
Isolation and cultivation of MSCs from umbilical cord was as
described by Widowati et al,10 fresh human umbilical cords
(UC; n Z 5) were obtained from women aged 25e40 years
after full-term births (normal vaginal delivery), all donors
signed a written informed consent, and guidelines were
approved by the Institutional Ethics Committee at the Stem
Cell and Cancer Institute, Jakarta, Indonesia and from
the Institutional Ethics Committee collaboration between
Maranatha Christian University, Bandung, Indonesia and
Immanuel Hospital Bandung, Bandung, Indonesia.
Isolated WJMSCs from UC were rinsed in normal saline
(0.9% w/v sodium chloride) and cut into very small explants
(1e2 mm), then plated on tissue culture plastic plates. The
explants were cultured in minimum essential medium-a
with 2 mM GlutaMAX (Invitrogen, Carlsbad, CA, USA), sup-
plemented with 20% fetal bovine serum (FBS; Invitrogen)
and penicilline streptomycine amphotericin B (100 U/mL,
100 mg/mL, and 0.25 mg/mL; Invitrogen). Cultures were
incubated in a humidified atmosphere with 5% CO2 at 37C,
replacing medium every 5 days for 21 days. The cells were
harvested and replated at a density 8  103 cells/cm2 when
cells reached 80e90% confluence. WJMSCs were cultured in
95% air (21% O2), and 5% CO2 for normoxic and hypoxic
conditions (5% O2 and 2.5% O2).
10,15Cell surface phenotype and multipotent
differentiation
To confirm the effect of oxygen concentration (hypoxia and
normoxia) on MSCs characterization. The WJMSCs of passage
4 and 8 (P4 and P8) were characterized the surface marker
CD105, CD73, CD90, CD34, CD45, CD14, CD19, and HLA-II
using a flow cytometer. WJMSCs at 80% confluence were
harvested and dissociated with trypsin-EDTA and centri-
fuged at 300g for 10 minutes. The pellet was resuspended
with phosphate buffered saline (PBS) þ 2% FBS, and cells
were counted with a hemocytometer. Between 100 cells and
200 cells in 25 mL PBS were stained with the appropriate
surface monoclonal antibodies. Isotype controls were used
to determine background staining. These antibodies were as
follows: PE (Phycoerythrin) conjugated: CD105 (abcam
10 W. Widowati et al.53321-100), CD73 (BD550257), CD 90 (abcam 226), CD 34 (BD
348053), CD45 (BD 555482), CD14 (abcam 28061-100), CD 19
(abcam 1168-500), and HLA-DR (abcam 23901); FITC-
conjugated: mIgG1 (BD349041 and BD 349043), and mIgG2
(BD349053) then added to each FACS tube: isotype mIgG2a-
PE, CD105-PE, HLA class II-PE; isotype mIgG1-PE, CD73-PE,
CD19-PE; isotype mIgG1-FITC, CD 34-FITC, CD45-FITC,
CD14-FITC, after incubation at 4

C for 15 minutes. The cells
were analyzed by flow cytometry with a FACS CaliburTM 3
argon laser 488 nm (Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA) using CellQuest Pro Acquisition on the BD
FACStationTM Software. The experiments and measurement
of surface marker were performed in triplicate.10
For osteogenic differentiation, WJMSCs (P4 and P8) were
seeded at density 1  104 cells/cm2 in culture dishes using
StemPro Osteogenesis Differentiation Kit (Gibco A10072-01,
Invitrogen) for 3 weeks. Calcium deposits were visualized
using Alizarin red S (Biochemicals and Life Science Research
Products, Amresco 9436). For chondrogenic differentiation
of WJMSCs were seeded at density 1  104 cells/cm2 in
culture dishes using StemPro Chondrogenesis Differentiation
Kit (Gibco A10071-01, Invitrogen) for 2 weeks. Chondrocytes
were visualized using Alcian blue (Amresco, 0298). Adipo-
genic differentiation of WJMSCs was done using StemPro
Adipogenesis Differentiation Kit (Gibco A10070-01, Invi-
trogen, Carlsbad, CA, USA) for 2 weeks. We used Oil Red O
(Sigma 00625, St Louis, USA) to confirm lipid droplets.16e18
Preparation of conditioned media from normoxia-
or hypoxia-treated WJMSCs
WJMSCs of P4 were used for the experiments. The WJMSCs
were seeded at a density of 8  103 cells/cm2 under nor-
moxia (20% O2 and 5% CO2) and hypoxia (5% O2 and 20% CO2)
for 72 hours; when cultures reached 80e90% confluence,
cells were harvested. The medium was collected and
centrifuged at 3000g for 4 minutes at room temperature,
and the supernatant was filtered by a 0.22-mm MillexeGV
Filter Unit with Durapore (SLGV 033 RS, Millipore Corpora-
tion, Billerica, MA, USA) and used as WJMSCs-CM.18,19
Anticancer assay
The cancer cell lines of cervical (HeLa- ATCC CCL-2), liver
(HepG2- ATCC HB-8065), prostate (PC3-ATCC CRL-1435),
ovarian (SKOV3-ATCC HTB-77), oral squamous (HSC3; ATCC,
Manassas, VA, USA), mouse fibroblast (NIH3T3-ATCC CRL-
1658), human fibroblast (primary cells), and hMSCs (primary
cells fromWharton’s jelly) were obtained from Stem Cell and
Cancer Institute, Jakarta, Indonesia. The cells were grown
and maintained in Dulbecco modified Eagle’s medium sup-
plemented with 10% FBS (Invitrogen), 100 U/mL penicillin
(Invitrogen), and 100 mg/mL streptomycin (Invitrogen), and
incubatedat37C inahumidifiedatmosphereand5%CO2.
20,21
The cell viability assay uses an optimized reagent con-
taining resazurin converted to fluorescent resorufin by viable
cells that absorbs the light at 490 nm. Briefly, cells were
seeded at density 5  103 in 96-well plates for 24 hours of
incubation20,21; cells were supplemented by WJMSCs-norCM
and WJMSCs-hypoCM in various concentrations (100%, 75%,
50%, and 0%) then incubated for 72 hours. The anticanceractivity of WJMSCs-CM was noted for cancer cell lines
including HeLa, HepG2, PC3, SKOV3, HSC3. We used NIH3T3,
human fibroblast, and hMSCs as controls to determine the
cytotoxic effect of WJMSCs-CM in normal cells. MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] assay (Promega, Madison,
WI, USA) was used to determine cell viability. MTSwas added
at 10 mL to each well. The plate was incubated at 5% CO2,
37C for 4 hours. The absorbance of the cells was measured
at 490 nm using a microplate enzyme-linked immunosorbent
assay reader (Multiskan Go, Thermo Scientific, USA). The
data were presented as number of viable cells and the per-
centage of viability.20,21
Statistical analysis
To verify the statistical significance of all parameters, the
data were calculated and expressed in means and standard
deviation (M  SD). To compare treatments, analysis of
variance (ANOVA) was used, and p < 0.05 were considered
as statistically significant, along with Tukey honestly sig-
nificant difference post hoc test and 95% confidence in-
terval. The median inhibitory concentration (IC50) of
cytotoxic effect was analyzed using probit analysis. Statis-
tical analysis used the SPSS version 20.0 program (IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp,
SPSS Inc., Chicago, IL, USA).
Results
MSC markers by cell surface phenotype
Flow cytometry analysis showed that for cultured cells
under normoxia and hypoxia (5% O2) for P4 and P8, WJ-MSCs
were positive for MSCs marker CD105, CD73, and CD90 and
negative for CD34, CD45, CD14, CD19, and HLA-II. The ef-
fect of oxygen level (normoxic and hypoxic 5% O2) and
passage (early passage P4 and late passage P8) on the
surface marker of WJMSCs can be seen in Table 1. Surface
marker expression of WJ-MSCs (P4 and P8) on hypoxia and
normoxia were not significantly different (p > 0.05).
MSC differentiation
We examined the differentiation potentials (osteogenic,
chondrogenic, and adipogenic differentiation) that were
cultured in either normoxic (20% O2 and 5% CO2) or hypoxic
(5% O2 and 2.5%O2) conditions. After 3 weeks, WJMSCs were
cultured in osteogenesis differentiation medium, and the
differentiated WJMSCs responses to either normoxia or
hypoxia exhibited calcium deposits based on the staining of
Alizarin red S. After 2 weeks, WJMSCs were cultured in
chondrogenesis differentiation medium, and the differen-
tiated WJMSCs in responses to either normoxia or hypoxia
exhibited chondrocyte expression using Alcian blue. After 2
weeks, WJ-MSCs were cultured in adipogensis differentia-
tion medium in response to either normoxia or hypoxia and
exhibited lipid droplets using Oil Red O (Fig. 1).
Fig. 1 shows that WJ-MSCs incubated in normoxia (21%
O2) and hypoxia (5% O2 and 2.5% O2) differentiated to
osteocyte, adipocyte, and chondrocyte.
Table 1 Effect of oxygen level and type of passage toward surface markers for umbilical cord mesenchymal stem cells derived
from human umbilical cord Wharton’s jelly.
Surface markers of WJMSCs Passage 4 Passage 8
Normoxia Hypoxia 5% Normoxia Hypoxia 5%
CD105 96.00  1.39 96.88  0.11 95.65  1.77 95.07  3.33
CD73 96.67  2.25 97.30  2.55 96.40  3.11 97.63  0.45
CD90 96.17  1.00 96.70  0.71 96.55  1.77 96.57  1.95
CD34 0.00  0.00 0.04  0.05 0.00  0.00 0.00  0.01
CD45 0.00  0.00 0.05  0.06 0.00  0.00 0.00  0.00
CD14 0.00  0.00 0.01  0.01 0.01  0.01 0.00  0.01
CD19 0.39  1.12 0.12  0.11 0.80  1.24 0.15  0.21
HLA-II 0.23  0.40 0.00  0.00 0.00  0.00 0.03  0.05
Data are presented as mean  standard deviation of surface markers of WJ-MSCs.
WJMSCs Z mesenchymal stem cells derived from Wharton’s jelly.
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To determine the effect of bothWJMSCs-norCM andWJMSCs-
hypoCM toward various cancer cell lines (HeLa, HepG2, PC3,
SKOV3, and HSC3) and normal cells (NIH3T3, human fibro-
blast, and hMSCs), the cell lines were cultured at density
5 103 in a 96-well plate.We determined the cell viability by
MTS assay. WJMSCs-norCM and WJMSCs-norCM exhibited
decreased viability in cancer cell lines in a concentration-
dependent manner. The effect of WJMSCs-norCM and
WJMSCs-hypoCM on the number of cancer cells can be seen
in Table 2. The number of cancer cells decreased along with
treatments, and the higher WJMSCs-CM concentration
decreased the number of cancer cells. The effect of
WJMSCs-norCM and WJMSCs-hypoCM toward inhibition of
cancer cell viability can be seen in Table 3. As seen in Table
3, WJMSCs-norCM and WJMSCs-hypoCM could inhibit the
proliferation of cancer cells including HeLa, HepG2, PC3,
SKOV3, and HSC3 in a concentration-dependent manner.
The IC50 value of WJMSCs-norCM and WJMSCs-hypoCM
(concentration of anticancer candidate, which could inhibit
50% cell proliferation) was found to be 51.690e81.440%
(Table 4). Each sample (WJMSCs-norCM and WJMSCs-
hypoCM) was done in triplicate and inhibition data were
analyzed using probit analysis to obtain the IC50. As shown in
Table 4, WJMSCs-norCM and WJMSCs-hypoCM exhibited a
cytotoxic effect toward HeLa, HepG2, PC3, SKOV3, and HSC3
cells, and the highest anticancer activity was WJMSCs-
hypoCM in HepG2 with IC50 51.690% and in HeLa with IC50
61.425%. The highest anticancer activity of WJMSCs-norCM
with IC50 was 64.424% in HepG2. WJMSCs-hypoCM had
higher anticancer activity to inhibit HeLa, HepG2, pc3, and
hsc3 cell lines compared to WJMSCs-norCM.
The selective cytotoxic effect of WJMSCs-norCM and
WJMSCs-hypoCM was carried out in NIH3T3, human fibro-
blast, and hMSCs. The effect of WJMSCs-norCM and
WJMSCs-hypoCM on the number of normal cells can be seen
in Table 5. The effect of WJMSCs-hypoCM and WJMSCs-
norCM on inhibition of normal cells can be seen in
Table 6. The IC50 value of WJMSCs-norCM and WJMSCs-
hypoCM was found to be 136.290e185.339% (Table 7). As
shown in Tables 5e7, WJMSCs-norCM and WJMSCs-hypoCM
demonstrated a low cytotoxic effect, inhibited low cell
proliferation in normal cells, including NIH3T3, humanfibroblast cells, and hMSCs. WJMSCs-norCM and WJMSCs-
hypoCM were not toxic toward normal cells with
IC50>100% concentration of CM.
Discussion
WJ-MSCs was positive for CD105, CD73, and CD90 and
negative for CD34, CD45, CD14, CD19, and HLA-II (Table 1).
These data were consistent with previous research that
hMSCs highly expressed CD105, CD73,1,10 and CD9022 and
had low expression of CD34, CD45, CD14, CD19, and HLA-
II.1,10,22 The surface marker of WJMSCs of P4 and P8 both
normoxic and hypoxic 5% O2 were not significantly different
(p > 0.05); these data are consistent with previous research
that surface markers expression are positive for CD105,
CD73, and CD90 (>95%) and negative for CD34, CD45, CD14,
CD19, and HLA-II (<2%).10,16
Pluripotency was confirmed by the ability of WJ-MSCs
cells to differentiate into osteocytes, chondrocytes, and
adipocytes.24 As demonstrated in Fig. 1, both nor-WJMSCs
and hypo-WJMSCs differentiated to osteocytes, chon-
drocytes, and adipocytes; these findings were consistent
with previous research that MSCs possess an extensive po-
tential to proliferate and differentiate. into osteocytes,
adipocytes, and chondrocytes.22,24e26 MSCs can also be
isolated from umbilical cord Wharton’s jelly and markers
expressed by flow cytometry; differentiate into osteoblast,
adipocyte- and chondrocyte-like cells; and exhibit multi-
potent differentiation potential.27
After 2 weeks of exposure to adipogenesis induction
medium, cells began to show a round shape and most of
them contained cytoplasmatic vacuoles, intracellular
accumulated lipids, and small oil droplets in the cytoplasm
that were positive with Oil Red O staining (Fig. 1B, E, H, K,
N, and Q). Control cells grew with proliferative medium
were negative with Oil Red O staining (Fig. 1T and W).18,28,29
These data were validated with previous research, which
found that reverse transcription-polymerase chain reaction
analysis of adipogenic gene expression also revealed similar
degrees of upregulation of lipoprotein lipase, adipocyte
fatty acid-binding protein 2 (aP2), and peroxisome
proliferator-activated receptor g2 (PPAR g2).18,30
After 3 weeks of osteogenic induction, the cells pro-
duced mineralized matrix by Alizarin red S staining (Fig. 1A,
Figure 1 Morphological appearance of osteogenic, adipogenic and chondrogenic differentiation of WJ-norMSCs (normoxia-
treated WJ-MSCs) and WJ-hypoMSCs (hypoxia-treated WJ-MSCs) at P4 and P8. For each differentiation protocol, undifferenti-
ated cells were kept as controls (S,T,U,V,W,X).
12 W. Widowati et al.D, G, J, M, and P), cells displayed bone-like nodular ag-
gregates of matrix mineralization,25 and were absent in
control cultures28 (Fig. 1S and V). These data are consistent
with those of a previous study finding that reverse
transcriptase-polymerase chain reaction analysis of osteo-
genic gene expression also revealed similar levels of upre-
gulation of osteopontin and osteocalcin.18
The chondrogenic potential of the MSCs was confirmed
with the presence of acidic proteoglycans; it was observed
after 2 weeks of chondrogenic differentiation by Alcian
blue staining,23,31 for chondrogenic extracellular matrixcontaining hyaluronic acids31 (Fig. 1C, F, I, L, O, and R), the
negative controls of chondrogenic differentiation of
WJMSCs were represented by MSCs of P4 and P8 not
cultured into differentiation media31 (Fig. 1U and X). Ac-
cording to Fig. 1, WJMSCs of early passage and late passage
differentiated to osteocytes, chondrocytes, and adipo-
cytes; these data were validated with the previous finding
that MSCs could be expanded to 10 or 11 passages.32
Tables 2e4 showthatWJMSCs-norCMandWJMSCs-hypoCM
were able to inhibit the proliferation of various cancer cells
(cervical, liver, prostate, ovarian, and oral squamosa) with
Table 2 Effect of WJMSCs-norCM and WJMSCs-hypoCM toward number of cancer cells.
Cancer cells Number of cells
Normoxia Hypoxia
FBS 10%
(WJMSCs-norCM 0%)
WJMSCs-norCM
50%
WJMSCs-norCM
75%
WJMSCs-norCM
100%
WJMSCs-hypoCM 0% WJMSCs-hypoCM
50%
WJMSCs-hypoCM
75%
WJMSCs-hypoCM
100%
HeLa 21,900  591d 16,273  3,340c 11,863  419b 1,343  211a 24,913  2,012d 16,216  240c 10,280  326b 1,670  55a
HepG2 21,508  912c 12,692  940b 12,968  775b 2,332  270a 24,062  630c 11,392  959b 10,952  1,466b 5,152  167a
PC3 20,701  456d 19,361  1,057c 15,081  172b 3,051  199a 22,748  1,522d 19,888  584c 12,778  120b 984  127a
SKOV3 18,105  1,385d 11,229  864b 12,902  196c 1,892  96a 17,959  2,082c 17,115  725c 12,632  150b 2,982  795a
HSC3 18,528  3,041c 15,515  491b 12,885  530b 918  30c 17,625  3,168d 13,985  266c 7,865  230b 938  334a
Data are expressed as mean  standard deviation, different letters in the same row (among concentrations of WJMSCs-norCM and among concentrations of WJMSCs-hypoCM) are significant
differences at p < 0.05 (Tukey honestly significant difference post hoc test).
FBS Z fetal bovine serum; WJMSCs Z mesenchymal stem cells derived from Wharton’s jelly; WJMSCs-hypoCM Z hypoxia-treated WJMSCs conditioned medium; WJMSCs-
norCM Z normoxia-treated WJMSCs conditioned medium.
The data (number of cancer cells) are expressed as mean  standard deviation, different superscript letters in the same row (a, b, c, d) are significant differences at p < 0.05 (Tukey
honestly significant difference post hoc test). Among the means of groups (type of cancer cell lines in normoxia or hypoxia).
Table 3 Effect of WJMSCs-norCM and WJMSCs-hypoCM toward inhibition of cancer cells.
Cancer cells Inhibition (%)
Normoxia Hypoxia
FBS 10%
(WJMSCs-norCM 0%)
WJMSCs-norCM
50%
WJMSCs-norCM
75%
WJMSCs-norCM
100%
WJMSCs-hypoCM
0%
WJMSCs-hypoCM
50%
WJMSCs-hypoCM
75%
WJMSCs-hypoCM
100%
HeLa 0.00  2.70a 25.69  5.25b 45.83  1.91c 93.87  0.96d 0.00  8.08a 34.91  0.96b 58.74  1.31c 93.30  0.22d
HepG2 0.00  4.24a 40.99  4.37b 39.70  3.60b 89.16  1.26c 0.00  2.62a 52.66  3.98b 54.49  6.09b 78.59  0.69c
PC3 0.00  2.20a 6.47  0.51b 27.15  0.83c 85.26  0.96d 0.00  6.69a 12.57  2.57b 43.83  0.53c 95.67  0.56d
SKOV3 0.00  7.65a 37.98  4.77b 28.74  1.08b 89.55  0.53c 0.00  11.59a 4.70  4.03a 29.66  0.83b 83.40  4.43c
HSC3 0.00  16.41a 16.26  2.65b 30.46  2.86b 95.05  0.16c 0.00  17.98a 20.65  1.51b 55.38  1.31c 94.68  1.90d
Data are expressed as mean  standard deviation, different letters in the same row (among concentrations of WJMSCs-norCM, among concentrations of WJMSCs-hypoCM) are significant
differences at p < 0.05 (Tukey honestly significant difference post hoc test).
FBS Z fetal bovine serum; WJMSCs Z mesenchymal stem cells derived from Wharton’s jelly; WJMSCs-hypoCM Z hypoxia-treated WJMSCs conditioned medium; WJMSCs-
norCM Z normoxia-treated WJMSCs conditioned medium.
The data (inhibition of cancer cells) are expressed as mean  standard deviation, different superscript letters in the same row (a, b, c, d) are significant differences at p < 0.05 (Tukey
honestly significant difference post hoc test). Among the means of groups (type of cancer cell lines in normoxia or hypoxia).
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Table 4 The IC50 of WJMSCs-norCM and WJMSCs-hypoCM
in various cancer cell lines for 72 hours of incubation.
Cancer cell lines IC50 (%)
WJMSCs-norCM WJMSCs-hypoCM
HeLa 67.77 61.43
HepG2 64.42 51.69
PC3 80.97 71.86
SKOV3 74.43 81.44
HSC3 74.19 66.93
IC50 Z median inhibitory concentration; WJMSCs Z mesen-
chymal stem cells derived from Wharton’s jelly; WJMSCs-
hypoCM Z hypoxia-treated WJMSCs conditioned medium;
WJMSCs-norCM Z normoxia-treated WJMSCs conditioned
medium.
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14 W. Widowati et al.various activities. These data were validated with previous
studies that hMSCs can be used for neoplastic transformation
and can be developed for novel anticancer therapeutics33;
human Wharton’s jelly stem cells inhibited certain solid
tumors.4,34e36 UCMSCs significantly inhibit proliferation of
cancer cell lines by in vivo and in vitro assay.4,37 Unengi-
neered human and rat UC-MSCs significantly attenuate pro-
liferation of breast cancer cell lines in vitro and in vivo,4 rat
mammary tumor cells,37 human lung cancer cells,38 mouse
Lewis lung carcinoma cells,39 and mouse pancreatic carci-
noma cells.5,40 Human umbilical cord mesenchymal stem
cells (hUCMSCs) are able to inhibit breast cancer cell prolif-
eration (MDA-MB-231) in a severe combined immunodefi-
ciency (SCID)mousemodel through secretion of dickkopf and
suppression of the Wnt pathway.35 hWJMSCs-conditioned
medium (hWJSC-CM; 50%) or hWJSCs-cell lysate (hWJSC-CL)
15 mg/mL for 48e72 hours inhibit cancer cell proliferation in
breast adenocarcinoma (MDA-MB-231), ovarian carcinoma
(TOV-112D), and osteosarcoma (MG-63) cells. The cancer cell
lines exhibited cell shrinkage, blebbing, and vacuolations
compared to controls.41 The inhibition was 20e26% and
31e46% for hWJSC-CM and hWJSC-CL, respectively, for all
three cancer cell lines. Cell cycle assays show increases in
sub-G1 and G2/M phases for all three cancer cell lines sug-
gestive of apoptosis and metaphase arrest.41 hWJSCs
migrated to metastatic tumor sites in the lungs and reduced
tumor burden after hWJSCswere administered intravenously
8 days after tumor transplantation in a rat model.4,37,42
Engineered hWJSCs-expressed human interferon-b inhibited
breast tumor growth in animal models.43 hWJSCs inhibit
human mammary carcinoma proliferation.41
Conditioned medium and cell-free lysate of hWJSCs
(hWJSC-CM and hWJSC-CL) inhibit the growth of a range of
cancer cells, including breast cancer (MDA-MB-231) and
ovarian cancer cells (TOV-112D), as well as osteosarcoma
cells (MG-63).41 Exposure of the osteosarcoma cell lines
SKES-1 and MG-63 to hWJSC-CL and hWJSC-CM results in cell
death and significant growth inhibition in vitro. At the
molecular level, there is a simultaneous upregulation of
proapoptotic and autophagy-related genes, such as BAX,
ATG-5, and BECLIN-1, and downregulation of prosurvival
genes, such as BCL-2 and SURVIVIN. In vivo, there was a
notable reduction in mammary tumor sizes and weights in
immunodeficient mice at 6 weeks after the injections of
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Table 7 The median inhibitory concentration IC50 of
WJMSCs-norCM and WJMSCs-hypoCM in various normal cells
for 72 hours of incubation.
Normal cells IC50 (%)
WJMSCs-norCM WJMSCs-hypoCM
NIH3T3 136.29 159.33
Human fibroblast 148.47 152.48
MSCs 140.44 185.34
IC50 Z median inhibitory concentration; MSCs Z mesenchymal
stem cells; WJMSCs Z mesenchymal stem cells derived from
Wharton’s jelly; WJMSCs-hypoCM Z hypoxia-treated WJMSCs
conditioned medium; WJMSCs-norCM Z normoxia-treated
WJMSCs conditioned medium.
Conditioned medium inhibits cancer cell proliferation 15hWJSC-CL and hWJSC-CM into these tumors. These findings
suggest that hWJSC-CL and hWJSC-CM may interfere with
the growth of mammary carcinoma and osteosarcoma cells
via apoptosis and autophagy.41 A similar cell death mech-
anism is observed during co-culture of WJMSCs with the
prostate cancer cell line (PC3). In the presence of WJMSCs,
PC3 cells exhibit caspase 9/3, PARP, and BAX induction, c-
Jun NH2-terminal kinase (JNK) activation, as well as a
decrease in phosphatidylinositol 3-kinase (PI3K)/AKT (also
known protein kinase B (PKB)) and extracellular signal-
regulated kinase (ERK) phosphorylation. Simultaneously,
there is a downregulation of prosurvival gene expressions,
such as BCL-2, BCL-XL, SURVIVIN, Mcl-1, and cIAP-1.4,44e47
The tumoricidal activity of hWJSCs-CM is probably
mediated by certain soluble factors secreted by these cells
into their extracellular environment, such as interleukins,
cell adhesion molecules, hyaluronic acid, growth factors,
and glycosoaminoglycans.44,48,49 Indeed, proteomic analysis
of hWJSC-CM shows significantly high levels of interleukins
(IL-1a, IL-6, IL-7, and IL-8), stem cell factor, human growth
factor, and intercellular adhesion molecule-1.44 Moreover,
the extracellular matrix of WJMSCs also contains dickkopf-
1, a protein known to suppress the Wnt signaling
pathway.35,48 Likewise, bone marrow MSCs conditioned
medium suppresses the proliferation of two hepatoma cell
lines in vitro and induces tumor regression in a hepatoma
SCID mouse xenograft model by means of Wnt signaling
pathway regulations.45,47,48 Engineered bone marrow MSCs
are found to secrete IL-12, which inhibits the growth of
melanoma and cervical cancer cells through the induction
of a tumor-specific T cell response in vivo.45 Moreover, bone
marrow MSCs also express several suicide genes, which halt
the proliferation of prostate cancer cells in an athymic
murine model.45 In addition to the upregulation of several
proapoptotic and tumor suppressor genes in hWJSCs, tran-
scriptomic studies have also found an increased expression
of several cytokines in these cells, such as IL-12a, which are
thought to induce apoptosis and thereby mediate the
anticancer effects of hWJSCs, hWJSC-CM, and hWJSC-
CL.50,51
The IL-12 gene promoted the activation of the cellular
immune response via expression of a Th1-type cytokine
profile and was associated with the inhibition of tumor
growth.3,52 IL-12 treatment represents a novel approach
for gene therapy against cervical cancer.51 IL-8 of hWJSCs
killed the cancer cells.41 Hyaluronan oligosaccharides
16 W. Widowati et al.inhibited the growth of osteosarcoma cell lines (MG-63 and
LM-8)53 and glycosoaminoglyans inhibited the cell prolifer-
ation of osteoblasts and osteosarcoma cells.54
UC-MSCs expressed the multiple tumor suppressor gene.5
hUCMSC are able to inhibit human breast cancer cells by
attenuating primarily the AKT and mitogen-activated pro-
tein kinase pathways and stimulating the intrinsic apoptosis
pathway.5 hUCMSC attenuated the growth of cancer cells
and mainly by attenuation of Erk-1/2 and PI3K/AKT
signaling and intrinsic apoptosis.5
Nor-WJMSCs and hypo-WJMSCs from P4 and P8 showed
no significant differences in MSCs surface marker expres-
sion and MSCs differentiation. WJMSCs-norCM and WJMSCs-
hypoCM could inhibit cells proliferation in various cancer
cell lines, and were not toxic for normal cells.
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